Human RANKL ELISA Kit (A302604)

Name: Human RANKL ELISA Kit
Brand: Antibodies.com
SKU: A302604
Price: 550.0 GBP
Availability: InStock

1 Citation

Enlarge Image

$815

100% Guarantee

Price Match Guarantee

Shipping Information

Freight/Packing Charges: $40

Dispatched from St. Louis, MO.

Lead Time: 7-11 business days.

Name

Human RANKL ELISA Kit

Description

Human RANKL ELISA Kit (High Range) is a 4 hour sandwich Enzyme-Linked Immunosorbent Assay (sELISA) designed for the in vitro quantitative determination of high-abundance human RANKL in serum, plasma, tissue homogenates, and other biological fluids.

Assay Type

Sandwich (quantitative)

Principle of Assay

Human RANKL ELISA Kit (High Range) (A302604) is a 4 hour sandwich Enzyme-Linked Immunosorbent Assay (sELISA) designed for the in vitro quantitative determination of human RANKL in serum, plasma, tissue homogenates, and other biological fluids. A 96-well microtiter plate has been pre-coated with an antibody specific for RANKL. Standards and samples are added to the wells, where RANKL binds to the immobilized capture antibody. Following incubation, unbound components are removed by washing and a biotinylated detection antibody specific for RANKL is added to the wells. The detection antibody binds the captured RANKL to form an antibody-antigen-antibody sandwich complex. After further incubation and washing, HRP-Streptavidin conjugate is added to the wells. TMB substrate solution is then added to visualize the HRP enzymatic reaction. This produces a blue-coloured product that changes to yellow following addition of acidic stop solution. The intensity of the yellow colour is directly proportional to the amount of RANKL captured in each well. The concentration of RANKL is calculated by reading the absorbance at 450 nm and comparing the values with the standard curve.

Platform

Pre-coated Microplate (12 x 8 well strips)

Detection Type

Colorimetric Detection (OD450)

Instrument

Colorimetric Microplate Reader

Sample Type

Serum, plasma, tissue homogenates, and other biological fluids.

Sensitivity

9.375 pg/mL

Product Range

15.625-1000 pg/mL

Assay Time

4 hours

Reactivity

Human

Cross Reactivity

Specific for RANKL with no reported cross-reactivity with other analogs or variants.

Recovery

Sample Type	n	Range	Average
Serum	10	86% - 101%	93%
EDTA Plasma	10	93% - 105%	98%
Heparin Plasma	10	87% - 104%	97%

Linearity

Sample Type	n	1:2	1:4	1:8
Serum	10	85-104%	83-99%	82-99%
EDTA Plasma	10	91-105%	84-101%	88-100%
Heparin Plasma	10	87-99%	82-101%	85-97%

Storage

Shipped at +4°C. Store kit components at +4°C or -20°C as instructed in the Protocol Manual. Do not use past expiration date! Avoid freeze/thaw cycles.

Synonyms

CD254, ODF, OPGL, Osteoclast differentiation factor, Osteoprotegerin ligand, Receptor activator of nuclear factor kappa-B ligand, TNF-related activation-induced cytokine, TNFSF11, TRANCE, Tumor necrosis factor ligand superfamily member 11

Product Note

Information online is representative. Always refer to the Product Manual inside the kit.

Disclaimer

This product is for research use only. It is not intended for diagnostic or therapeutic use.

Kit Components

Item	Quantity	Storage
Pre-Coated 96 Well Microplate	12 x 8 Well Strips	+4°C
Lyopholized Standard	2 Vials	+4°C
Sample Dilution Buffer	20ml	+4°C
Biotinylated Detection Antibody	120µl	+4°C
Antibody Dilution Buffer	10ml	+4°C
HRP-Streptavidin Conjugate	120µl	+4°C
SABC Dilution Buffer	10ml	+4°C
TMB Substrate	10ml	+4°C
Stop Solution	10ml	+4°C
Wash Buffer (25X)	30ml	+4°C
Plate Sealers	5 Adhesive Strips	-
Foil Pouch	1 Zip-Sealed Pouch	-

Required Materials

The following materials are not included in the kit, but are required to run this assay:

Microplate reader capable of measuring absorbance at 450nm ± 10nm.
Squirt bottle, multichannel pipette reservoir, or automated microplate washer.
Graph paper or computer software capable of generating logarithmic functions.
Test tubes and Eppendorf tubes to prepare standards and samples.
Multi- and single-channel pipettes and sterile pipette tips.
Deionized or distilled water.
Absorbent paper towels.
37°C incubator.

Important Notes

Sample concentrations should be estimated before being used in the assay and a proper dilution factor should be selected to make the diluted target protein concentration fall in the optimal detection range of this kit.
Sample matrix components will interfere with the test results. All samples must be diluted at least 1:2 with Sample Dilution Buffer.
Hemolysis can greatly impact the validity of test results. Take care to minimize hemolysis.
This ELISA kit is intended for the analysis of biological samples and has not been validated for purified/recombinant proteins, industrial, or commercial materials. Performance with such samples cannot be guaranteed, as differences in expression, sequence, tags, folding, post-translational modifications, purity, activity, or buffer composition may affect assay results. For further guidance, please contact our technical support team.

Bring all reagents and samples to room temperature before use.

We recommend that all standards and samples be assayed in duplicate.

Step 1

Prepare all reagents, samples, and working standards as directed in the previous sections.

Step 2

Determine the number of microplate strips required for the assay and insert them into the plate frame. Unused strips should be stored in the foil pouch at +4°C.

Step 3

Add 100μl of standard solutions to the standard wells. Note: A plate layout is provided to record standards and samples assayed.

Step 4

Add 100μl of samples to the sample wells. Note: All samples must be properly diluted in order to produce sample values within the dynamic range of the assay. All samples must be diluted at least 1:2 with Sample Dilution Buffer.

Step 5

Cover with an adhesive plate sealer provided and incubate at 37°C for 90 minutes.

Step 6

Remove the plate sealer, aspirate the liquid from the plate, and wash the plate two times with Wash Buffer. Soak wells with 350μl of Wash Buffer for 1-2 minutes each time. Note: Complete removal of liquid at each step is essential to good performance. After the last wash, remove any remaining Wash Buffer by aspirating or decanting. Blot the plate onto paper towels or other absorbent material. Do not let the wells dry completely at any time!

Step 7

Add 100μl of Biotinylated Detection Antibody working solution to each well.

Step 8

Cover with a new adhesive plate sealer and incubate at 37°C for 60 minutes.

Step 9

Remove the plate sealer, aspirate the liquid from the plate, and wash the plate three times with Wash Buffer. Soak wells with 350μl of Wash Buffer for 1-2 minutes each time.

Step 10

Add 100μl of HRP-Streptavidin Conjugate (SABC) working solution to each well.

Step 11

Cover with a new adhesive plate sealer and incubate at 37°C for 30 minutes.

Step 12

Remove the plate sealer, aspirate the liquid from the plate, and wash the plate five times with Wash Buffer. Soak wells with 350μl of Wash Buffer for 1-2 minutes each time.

Step 13

Add 90μl of TMB Substrate to each well. Cover with a new adhesive plate sealer and incubate at 37°C in the dark for 10-20 minutes. Note: This incubation time is for reference only, the optimal reaction time should be determined by the end-user and can be shortened or extended according to the actual color change. The reaction may be terminated when a gradient is apparent in the standard wells. Do not exceed 30 minutes!

Step 14

Add 50μl of Stop Solution to each well. The color in the wells should change from blue to yellow immediately. Note: If the color in the wells is green or the color change does not appear uniform, gently tap the plate to ensure thorough mixing.

Step 15

Determine the optical density (O.D. value) of each well immediately using a microplate reader set to 450 nm.

Scientific Validation DataValidation Data (2)

Enlarge Image

Standard Curve - Human RANKL ELISA Kit (A302604)

Representative standard curve for Human RANKL ELISA Kit (A302604).

Enlarge Image

Human RANKL ELISA Kit (A302604)

Linearity assessment of the Human RANKL ELISA Kit (A302604) across serial sample dilutions. Linearity was evaluated using Serum, EDTA Plasma, and Heparin Plasma samples serially diluted from 1:2 to 1:8. Recovery (%) was calculated relative to the expected Human RANKL concentration at each dilution. Data are presented as mean recovery values from 10 replicates (n = 10).

Product Citations (1)

Enlarge Image

(2)

Effects of collagen peptide supplementation on bone turnover, cytokine, and inflammatory markers in female distance runners: a randomized pilot study

This publication cites Human RANKL ELISA Kit (A302604).

Article Abstract

Introduction: Female distance runners are at elevated risk for impaired bone remodeling due to high mechanical loading, potential low energy availability, and sustained inflammatory stress. Collagen peptide (CP) supplementation has been proposed as a nutritional strategy to support type I collagen synthesis and modulate osteoimmune signaling; however, evidence in premenopausal endurance athletes is limited. This pilot randomized, double-blind, placebo-controlled trial examined the effects of four weeks of high-dose CP supplementation on markers of bone metabolism and inflammatory activity in endurance-trained premenopausal women.

Methods: Twenty-two participants (18-35 years; =35 miles/week [>56km/week]) were randomized to CP (INT; 20 g/day) or isocaloric maltodextrin (CON). Pre- and post-intervention assessments, conducted in the early follicular phase, included serum procollagen type I N-terminal propeptide (P1NP), plasma C-terminal telopeptide of type I collagen (CTX-1), serum soluble receptor activator of nuclear factor-?B ligand (sRANKL), osteoprotegerin (OPG), the sRANKL/OPG ratio, and interleukin-6 (IL-6). Repeated-measures ANCOVAs were performed, adjusting for accumulated running distance and vitamin D status.

Results: A significant group × time interaction was observed for P1NP (p = 0.04), with increases in INT and no change in CON. No significant interaction was observed for CTX-1 (p = 0.13). Significant interactions were also observed for sRANKL (p = 0.046) and IL-6 (p = 0.03). No significant interaction effects were detected for sRANKL, OPG, or the sRANKL/OPG ratio.

Discussion: Short-term CP supplementation increased a marker of bone formation, altered osteoclast-related signaling, and reduced IL-6 in endurance-trained premenopausal women. These findings support the potential for CP-mediated modulation of bone turnover and inflammatory activity and warrant further investigation in larger, adequately powered trials incorporating structural bone outcomes.

View Publication

Publishing research using Human RANKL ELISA Kit (A302604)? Please let us know so that we can list the citation on this page.